BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30457049)

  • 1. The Potential of Receptor for Advanced Glycation End Products (RAGE) as a Therapeutic Target for Lung Associated Diseases.
    Khaket TP; Kang SC; Mukherjee TK
    Curr Drug Targets; 2019; 20(6):679-689. PubMed ID: 30457049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycation & the RAGE axis: targeting signal transduction through DIAPH1.
    Shekhtman A; Ramasamy R; Schmidt AM
    Expert Rev Proteomics; 2017 Feb; 14(2):147-156. PubMed ID: 27967251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.
    Oczypok EA; Perkins TN; Oury TD
    Paediatr Respir Rev; 2017 Jun; 23():40-49. PubMed ID: 28416135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The receptor for advanced glycation end-products enhances lung epithelial wound repair: An in vitro study.
    Zhai R; Blondonnet R; Ebrahimi E; Belville C; Audard J; Gross C; Choltus H; Henrioux F; Constantin JM; Pereira B; Blanchon L; Sapin V; Jabaudon M
    Exp Cell Res; 2020 Jun; 391(2):112030. PubMed ID: 32330509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury.
    Smit PJ; Guo WA; Davidson BA; Mullan BA; Helinski JD; Knight PR
    J Surg Res; 2014 Sep; 191(1):214-23. PubMed ID: 24814199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAGE Signaling in Inflammatory Disease.
    Hudson BI; Lippman ME
    Annu Rev Med; 2018 Jan; 69():349-364. PubMed ID: 29106804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAGE Signaling in Skeletal Biology.
    Plotkin LI; Essex AL; Davis HM
    Curr Osteoporos Rep; 2019 Feb; 17(1):16-25. PubMed ID: 30685821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ousting RAGE in melanoma: A viable therapeutic target?
    Syed DN; Aljohani A; Waseem D; Mukhtar H
    Semin Cancer Biol; 2018 Apr; 49():20-28. PubMed ID: 29079306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
    Leung SS; Forbes JM; Borg DJ
    Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases.
    Yue Q; Song Y; Liu Z; Zhang L; Yang L; Li J
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.
    El-Far AH; Sroga G; Jaouni SKA; Mousa SA
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.
    Prasad K
    Mol Cell Biochem; 2019 Sep; 459(1-2):95-112. PubMed ID: 31079281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    Yan SF; Ramasamy R; Schmidt AM
    J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease.
    Sharma A; Kaur S; Sarkar M; Sarin BC; Changotra H
    Clin Rev Allergy Immunol; 2021 Apr; 60(2):244-258. PubMed ID: 33170477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor for advanced glycation end products is targeted by FBXO10 for ubiquitination and degradation.
    Evankovich J; Lear T; Mckelvey A; Dunn S; Londino J; Liu Y; Chen BB; Mallampalli RK
    FASEB J; 2017 Sep; 31(9):3894-3903. PubMed ID: 28515150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis.
    Machahua C; Montes-Worboys A; Llatjos R; Escobar I; Dorca J; Molina-Molina M; Vicens-Zygmunt V
    Respir Res; 2016 Nov; 17(1):144. PubMed ID: 27816054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor for advanced glycation end products: a new theraputic target for chronic obstructive pulmonary disease?
    Chen L; Liu L; Wang T; Shen YC; Wen FQ
    Arch Med Res; 2013 Jan; 44(1):75-6. PubMed ID: 23287523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation.
    Huttunen HJ; Kuja-Panula J; Rauvala H
    J Biol Chem; 2002 Oct; 277(41):38635-46. PubMed ID: 12167613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
    Rao NV; Argyle B; Xu X; Reynolds PR; Walenga JM; Prechel M; Prestwich GD; MacArthur RB; Walters BB; Hoidal JR; Kennedy TP
    Am J Physiol Cell Physiol; 2010 Jul; 299(1):C97-110. PubMed ID: 20375277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diminished Circulating Levels of Angiogenic Factors and Rage Ligands in Helminth-Diabetes Comorbidity and Reversal Following Anthelmintic Treatment.
    Rajamanickam A; Munisankar S; Menon PA; Nutman TB; Babu S
    J Infect Dis; 2021 Nov; 224(9):1614-1622. PubMed ID: 33822083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.